256 related articles for article (PubMed ID: 30755668)
1. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9.
Kostyushev D; Kostyusheva A; Brezgin S; Zarifyan D; Utkina A; Goptar I; Chulanov V
Sci Rep; 2019 Feb; 9(1):1847. PubMed ID: 30755668
[TBL] [Abstract][Full Text] [Related]
2. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
3. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
4. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
Seeger C; Sohn JA
Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
6. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
7. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
Murai K; Kodama T; Hikita H; Shimoda A; Fukuoka M; Fukutomi K; Shigeno S; Shiode Y; Motooka D; Higuchi Y; Miyakawa K; Suemizu H; Ryo A; Tahata Y; Makino Y; Yamada R; Sakamori R; Tatsumi T; Takehara T
Hepatol Commun; 2022 Sep; 6(9):2474-2487. PubMed ID: 35608131
[TBL] [Abstract][Full Text] [Related]
9. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
[TBL] [Abstract][Full Text] [Related]
11. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
12. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection.
Zhang X; Tian Y; Xu L; Fan Z; Cao Y; Ma Y; Li H; Ren F
Hepatol Int; 2022 Apr; 16(2):306-315. PubMed ID: 35298777
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
[TBL] [Abstract][Full Text] [Related]
15. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
16. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
[TBL] [Abstract][Full Text] [Related]
17. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.
Tang L; Sheraz M; McGrane M; Chang J; Guo JT
PLoS Pathog; 2019 Apr; 15(4):e1007742. PubMed ID: 31026293
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
19. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
20. HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage.
Wang Y; Li Y; Zai W; Hu K; Zhu Y; Deng Q; Wu M; Li Y; Chen J; Yuan Z
Hepatology; 2022 May; 75(5):1275-1288. PubMed ID: 34779008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
